- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04708288
UM ESTUDO DE OBSERVAÇÃO PROSPECTIVO, MULTI-CENTRAL, DE BRAÇO ÚNICO, PÓS-MERCADO PARA AVALIAR A SEGURANÇA E O DESEMPENHO CLÍNICO DO STENT BILIAR E PANCREÁTICO BIODEGRADÁVEL ARCHIMEDES (Registry)
Significant experience with biodegradable materials has been reported in the orthopedic literature; in particular; biodegradable stents have been used in the endovascular and urologic epithelium. Stents are typically made from polymeric materials including Polylactic Acid (PLA), Polyglycolide (PGA), Polydioxanone (PDO), Polyethyleneglycol (PEG), Polycaprolactone (PCL), etc., which have been cleared or approved by the FDA and CE-marked as drug carriers, sutures, and bone fixatives. The material is degraded by hydrolysis in, e.g., lactic acid, which is removed from the body by normal metabolic pathways. In the field of gastroenterology, these stents were first introduced in patients with an esophageal stenosis with encouraging results, although esophageal hyperplasia was a frequently encountered complication.
For biliary applications, biodegradable stents have been evaluated in several in-vitro and animal studies that demonstrated that the stents were safe and well tolerated. These stents provided an adequate radial force and resulted in complete stricture resolution within several months. The stents did not show any signs of biliary hyperplasia or integration in the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the outer layer sloughs during the degradation process similarly to the exfoliation of human skin. Also, the stent could be removed from the bile duct, thus offering the possibility of extraction if necessary at various times after implantation.
In 2010, Petryl was the first to use a biodegradable stent in the human bile duct. A stent was successfully placed using percutaneous transhepatic cholangiograpy in two patients with a postsurgical intrahepatic biliary stricture. Transient cholangitis was the only complication encountered and during the two years of follow-up, the bile duct remained patent.
Later, Mauri et al. presented in 2013 and 2016 results of a 107 patient study on a polydioxanone biodegradable biliary stent. The results have been published in the Journal of the European Society of Radiology. The authors concluded that percutaneous placement of a biodegradable biliary stent is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period.
Prior to this study, the ARCHIMEDES device was assessed in the ARCHIMEDES Investigational study which has completed enrolment with 53 patients included, and the results are not yet published. In this study approximately half the stents were deployed in the bile duct (53%) and half in the pancreatic duct. All 53 patients have either completed, exited, or no longer have the study device. No patient remains in the study with a stent in place during the time of the last patient follow-ups. The study concluded without any device-related SAE. Bilirubin was reduced by 25.6%, which exceeded the >20% clinical success criterion, quality of life score improved from 3.7 to 7.9, procedural success was rated 1.4 (good to excellent), and technical success was achieved in all 53 patients.
Data from the ARCHIMEDES Investigational study was used for CE Mark approval, which was obtained in June 2018.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: NIta Gondaliya
- Número de telefone: +49 1716578285
- E-mail: ngondaliya@q3medical.com
Estude backup de contato
- Nome: Manfred Guelcher
- Número de telefone: +4941716578200
- E-mail: mguelcher@q3medical.com
Locais de estudo
-
-
-
Düsseldorf, Alemanha, 40217
- Recrutamento
- Evangelisches Krankenhaus Düsseldorf
-
Contato:
- Biljana Dimitrijevic, PhD
- Número de telefone: +49 (0)211919483 601
- E-mail: Biljana.Dimitrijevic@evk-duesseldorf.de
-
Contato:
- Carina Friesl
- E-mail: carina.friesl@evk-duesseldorf.de
-
Investigador principal:
- Dr. Thomas Veiser, PhD
-
-
-
-
-
Singapore, Cingapura, 308433
- Concluído
- Tan Tock Seng Hospital Pte Ltd,
-
-
-
-
-
Ljubljana, Eslovênia, 1000
- Recrutamento
- University Medical Center Ljubljana
-
Contato:
- Karin Pulevic, VS
- Número de telefone: +38615228515
- E-mail: karin.pulevic@kclj.si
-
Contato:
- Dr. Martina Jaklič, MD
- Número de telefone: +38615222037
- E-mail: martina.jaklic@kclj.si
-
Investigador principal:
- Dr Samo Plut, MD
-
-
-
-
-
Salamanca, Espanha, 37007
- Recrutamento
- Hospital Universitario de Salamanca
-
Contato:
- Solorzano Garcia Ignacio
- Número de telefone: 55400 +34 679441022
- E-mail: isolorzano.ibsal@saludcastillayleon.es
-
Investigador principal:
- Dr. Alberto Álvarez Delgado, MD, PhD
-
-
-
-
-
Helsinki, Finlândia, 00290
- Concluído
- HUS Helsinki University Hospital
-
-
-
-
-
Paris, França, 75015
- Ativo, não recrutando
- Hôpital Européen Georges-Pompidou HEGP Service d'Hépato-gastro-entérologie et endoscopies digestives
-
-
-
-
-
Afula, Israel, 1834111
- Concluído
- Emek Medical Center
-
-
-
-
-
Forlì, Itália, 47121
- Concluído
- AUSL Romagna Ospedale Morgagni - Pierantoni
-
Pavia, Itália, 27100
- Ativo, não recrutando
- Gastroenterology and Digestive Endoscopy Unit Fondazione I.R.C.C.S. Policlinico San Matteo
-
Roma, Itália, 00128
- Ativo, não recrutando
- UCBM - Campus Bio-Medico University
-
-
Milano
-
Rozzano, Milano, Itália, 20089
- Ativo, não recrutando
- Endoscopy Unit, Humanitas Research Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients that will respect the inlcusion criteria will be enrolled in the study.
Descrição
Inclusion Criteria:
- Patient eligible for implantation of a pancreatic or billiary stent prior to participate in the study and according to current guidelines
- Patient has provided a signed and dated informed consent (according to the laws and regualtions of the country in which the observational study is conducted)
Exclusion Criteria:
- Age < 18 y
- Inability to understand the purpose of the study or refusal to cooperate
- Not available for routine follow-up visits
- Pregnancy
- Currently participating in a confounding trial before reaching first endpoint.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine practice
Participants receiving commercially available ARCHIMEDES Biodegradable Biliary and Pancreatic as part of standard care. Safety outcomes are collected for post-marketing surveillance |
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine clinical practice |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Primary Safety endpoint
Prazo: From enrollment to the end of treatment, as per the standard of care.
|
Proportion of subjects experiencing procedure- or device-related complications within 30 days including Post-ERCP pancreatitis, Bleeding, Perforation (biliary/pancreatic/duodenal), Stent misplacement, Stent migration, Biliary occlusion, Cholangitis, Severe pain, All-cause death Within 30 days of the index procedure |
From enrollment to the end of treatment, as per the standard of care.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Secondary endpoints are defined as:
Prazo: Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care
|
Clinical success: patency rate as defined by the rate of freedom of stent replacements at follow-up time points defined by investigators definition of SOC (standard of care) or until planned bridge surgery (defined as no need of stent replacement). Technical success: Accurate stent deployment across the target stricture as evaluated by fluoroscopy and endoscopy. Procedural success will be quantified (using a dedicated score system, Excellence=1, Good=2, Fair=3, Poor=4) by the endoscopist post procedure using the following components:
|
Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- QM-NI-ABS-034
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .